XTX Topco Ltd Makes New $282,000 Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Key Points

• XTX Topco Ltd acquired a $282,000 stake in Taysha Gene Therapies, purchasing 203,129 shares, which represents approximately 0.10% ownership of the company.
• Wall Street analysts are optimistic about Taysha Gene Therapies, with average ratings of "Buy" and a consensus price target of $8.17.
• Major shareholder Paul B. Manning increased his holdings by purchasing 750,000 shares at an average price of $2.75, bringing his total ownership to 2,841,704 shares.

XTX Topco Ltd acquired a new position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 203,129 shares of the company's stock, valued at approximately $282,000. XTX Topco Ltd owned approximately 0.10% of Taysha Gene Therapies as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in TSHA. Avoro Capital Advisors LLC lifted its holdings in Taysha Gene Therapies by 7.2% in the 4th quarter. Avoro Capital Advisors LLC now owns 19,999,999 shares of the company's stock worth $34,600,000 after buying an additional 1,349,999 shares in the last quarter. Octagon Capital Advisors LP lifted its holdings in Taysha Gene Therapies by 128.6% in the 4th quarter. Octagon Capital Advisors LP now owns 10,450,000 shares of the company's stock worth $18,078,000 after buying an additional 5,877,778 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Taysha Gene Therapies by 7.8% in the 4th quarter. Vanguard Group Inc. now owns 8,906,764 shares of the company's stock worth $15,409,000 after buying an additional 641,305 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in Taysha Gene Therapies in the 4th quarter worth $8,650,000. Finally, Geode Capital Management LLC lifted its holdings in Taysha Gene Therapies by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 3,572,349 shares of the company's stock worth $6,182,000 after buying an additional 9,591 shares in the last quarter. Institutional investors and hedge funds own 77.70% of the company's stock.

Taysha Gene Therapies Stock Performance

NASDAQ TSHA remained flat at $2.94 during trading hours on Friday. 2,891,415 shares of the company's stock were exchanged, compared to its average volume of 2,845,960. Taysha Gene Therapies, Inc. has a 12-month low of $1.05 and a 12-month high of $3.31. The company has a quick ratio of 5.35, a current ratio of 12.48 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $631.11 million, a PE ratio of -8.65 and a beta of 0.98. The stock has a 50 day simple moving average of $2.60 and a 200 day simple moving average of $2.12.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.02). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 78.44%. The company had revenue of $1.99 million for the quarter, compared to the consensus estimate of $1.61 million. On average, equities research analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current year.

Insider Buying and Selling at Taysha Gene Therapies

In other Taysha Gene Therapies news, major shareholder Paul B. Manning acquired 750,000 shares of the company's stock in a transaction that occurred on Friday, May 30th. The shares were purchased at an average price of $2.75 per share, for a total transaction of $2,062,500.00. Following the completion of the purchase, the insider directly owned 2,841,704 shares in the company, valued at $7,814,686. The trade was a 35.86% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 3.78% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have commented on TSHA. Chardan Capital boosted their price objective on shares of Taysha Gene Therapies from $9.00 to $10.00 and gave the stock a "buy" rating in a report on Tuesday. JMP Securities boosted their price objective on shares of Taysha Gene Therapies from $5.00 to $6.00 and gave the stock a "market outperform" rating in a report on Thursday, May 29th. Citigroup reiterated an "outperform" rating on shares of Taysha Gene Therapies in a research note on Thursday, May 29th. Needham & Company LLC reiterated a "buy" rating and set a $8.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, July 1st. Finally, Wells Fargo & Company increased their price objective on shares of Taysha Gene Therapies from $7.50 to $8.00 and gave the company an "overweight" rating in a research note on Wednesday. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $8.29.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.